Search results for "KINASE"

showing 10 items of 2635 documents

Differential VASP phosphorylation controls remodeling of the actin cytoskeleton

2009

Proteins of the Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) family link signal transduction pathways to actin cytoskeleton dynamics. VASP is substrate of cAMP-dependent, cGMP-dependent and AMP-activated protein kinases that primarily phosphorylate the sites S157, S239 and T278, respectively. Here, we systematically analyzed functions of VASP phosphorylation patterns for actin assembly and subcellular targeting in vivo and compared the phosphorylation effects of Ena/VASP family members. Methods used were the reconstitution of VASP-null cells with `locked' phosphomimetic VASP mutants, actin polymerization of VASP mutants in vitro and in living cells, site-specific kinase-mediated…

macromolecular substancesBiologyCell LineMiceAnimalsHumansPhosphorylationCytoskeletonCytoskeletonActinMice KnockoutKinaseMicrofilament ProteinsEna/Vasp homology proteinsActin remodelingCell BiologyPhosphoproteinsActin cytoskeletonActinsCell biologyMice Inbred C57BLProtein TransportPhosphoproteinPhosphorylationCell Adhesion MoleculesResearch ArticleJournal of Cell Science
researchProduct

In vitro antitumor effects of the cold-water extracts of Mediterranean species of genus Pleurotus (higher Basidiomycetes) on human colon cancer cells

2014

The aim of this study was to evaluate whether the cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis (CWE-Pn), 2 of the most prized wild and cultivated edible mushrooms, can affect the tumor phenotype of human colon cancer HCT116 cells. Our results showed that treatment with CWE- Pef and CWE-Pn resulted in a significant inhibition of the viability of HCT116 cells and promoted apoptosis, as also demonstrated by the increase of Bax-to-Bcl-2 messenger RNA ratio. Moreover, we observed that both extracts were able to inhibit cell migration and to affect homotypic and heterotypic cell-cell adhesion. It also was found that treatment with CWE-Pef and CWE-Pn ne…

medicinal mushrooms Pleurotus eryngii var. ferulae Pleurotus nebrodensis human colon cancer antitumor activityCell SurvivalApoptosisPleurotusApplied Microbiology and BiotechnologySettore BIO/13 - Biologia ApplicataCell Line TumorVegetablesDrug DiscoveryExtracellularHumansPleurotus eryngiiCell Proliferationbcl-2-Associated X ProteinPharmacologyPleurotus nebrodensisPleurotusbiologyPlant ExtractsKinasebiology.organism_classificationAntineoplastic Agents PhytogenicIn vitroProto-Oncogene Proteins c-bcl-2BiochemistryApoptosisColonic NeoplasmsPhosphorylation
researchProduct

Cell Cycle: The Life Cycle of a Cell

2013

“Where a cell arises, there must be a previous cell”. This early statement of Rudolf Virchow already points to the process that is called cell cycle. It describes a series of events leading to cell division and duplication and can be sectioned into phases that are controlled by a collection of proteins interacting with each other, the cyclines and the cycline-dependent kinases. It is mandatory that DNA replication is conservative meaning that its structure and sequence remain unaltered while the DNA is duplicated before the cell actually divides. Checkpoints are responsible for the supervision, proteins such as p53 and RB being the key protagonists in cell cycle control. Upon DNA damage rec…

medicine.anatomical_structureCell cycle checkpointbiologyCell divisionCyclin-dependent kinaseDNA damageCellmedicinebiology.proteinDNA replicationCell cycleCyclinCell biology
researchProduct

Casein kinase 2 governs the molecular decision between Th17 cell and Treg cell development and controls encephalitogenicity of Th17 cells in experime…

2014

medicine.anatomical_structureNeurologyImmunologyExperimental autoimmune encephalomyelitisCellmedicineImmunology and AllergyNeurology (clinical)BiologyCasein kinase 2medicine.diseaseTreg cellCell biologyJournal of Neuroimmunology
researchProduct

Synthesis and biological evaluation of sphingosine kinase 2 inhibitors with anti-inflammatory activity.

2019

The synthesis of inhibitors of SphK2 with novel structural scaffolds is reported. These compounds were designed from a molecular modeling study, in which the molecular interactions stabilizing the different complexes were taken into account. Particularly interesting is that 7‐bromo‐2‐(2‐phenylethyl)‐2,3,4,5‐tetrahydro‐1,4‐epoxynaphtho[1,2‐b]azepine, which is a selective inhibitor of SphK2, does not exert any cytotoxic effects and has a potent anti‐inflammatory effect. It was found to inhibit mononuclear cell adhesion to the dysfunctional endothelium with minimal impact on neutrophil–endothelial cell interactions. The information obtained from our theoretical and experimental study can be us…

medicine.drug_classCell SurvivalNeutrophilsFísico-Química Ciencia de los Polímeros ElectroquímicaCellAnti-Inflammatory AgentsPharmaceutical ScienceSYNTHESIS01 natural sciencesPeripheral blood mononuclear cellAnti-inflammatoryANTI-INFLAMMATORY ACTIVITYchemistry.chemical_compoundStructure-Activity RelationshipDrug DiscoverymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsCytotoxic T cellHumansMOLECULAR MODELINGAzepineEnzyme Inhibitors010405 organic chemistryBIOASSAYSCiencias QuímicasSphingosine Kinase 2AdhesionAzepines0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistrySPHK2Phosphotransferases (Alcohol Group Acceptor)medicine.anatomical_structurechemistrySPHINGOSINE KINASE 2 INHIBITORSDrug DesignCancer researchEpoxy CompoundsEndothelium VascularCIENCIAS NATURALES Y EXACTASProtein BindingArchiv der Pharmazie
researchProduct

Mechanisms of arachidonic acid induced glial swelling

2000

Accumulation of arachidonic acid (AA) in the brain during ischaemia may contribute to development of brain oedema. In this study we investigated the effect of selected drugs on AA-induced cytotoxic brain oedema in C6 glioma cells. Suspended C6 glioma cells were preincubated with drugs and AA (0.1 mM) was added. When no drug was administered cell volume increased immediately after the addition of AA with a maximum cell swelling of 13.1+/-1.9% at 15 min (mean +/- S.E. M.). Preincubation of cells with BW 755C, a dual inhibitor of cyclo- and lipoxygenases, showed no reduction in cell swelling from AA, whereas superoxide dismutase, amiloride and the protein kinase inhibitor H-9370 led to a signi…

medicine.drug_classModels Neurological45-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amineBrain EdemaPharmacologyAmilorideSuperoxide dismutaseCellular and Molecular Neurosciencechemistry.chemical_compoundTumor Cells CulturedmedicineAnimalsCytotoxic T cellEnzyme InhibitorsOuabainMolecular BiologyCell SizeArachidonic AcidbiologySuperoxide DismutaseGliomaProtein kinase inhibitorIn vitroAmiloridemedicine.anatomical_structurechemistryCell cultureImmunologybiology.proteinNeurogliaArachidonic acidNeurogliamedicine.drugMolecular Brain Research
researchProduct

Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells

2021

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degr…

medicine.drug_classPharmaceutical Scienceacute myeloid leukemiaArticletranscriptomicsPharmacy and materia medicaDrug Discoverytyrosine kinase inhibitorsmedicineCytotoxic T cellnetwork pharmacologyddc:610biologyCrizotinibdrug repurposingChemistryTopoisomeraseRMyeloid leukemiaCell cyclemedicine.diseaseALK inhibitorRS1-441multiple myelomaLeukemiaCancer cellbiology.proteinCancer researchMolecular MedicineMedicinemedicine.drug
researchProduct

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

2019

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-aminopyridine functionality of crizotinib (essential for target kinase binding) was considered as ideal position for prodrug derivatization. Consequently, two different prodrugs were synthesized with the nitroimidazole unit attached to crizotinib either via carbamoylation (A) or alkylation (B) of the 2-aminopyridine moiety. The successful prodrug design could be proven by docking studies and a dr…

medicine.drug_classTyrosine kinase inhibitorAntineoplastic Agents01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitorStructure-Activity Relationshipchemistry.chemical_compoundDrug DevelopmentCrizotinibIn vivoDrug DiscoverymedicineHumansAnaplastic Lymphoma KinaseProdrugsHypoxiaProdrugProtein Kinase InhibitorsMolecular BiologyCells CulturedCell ProliferationNitroimidazoleDose-Response Relationship DrugMolecular StructureCrizotinib010405 organic chemistryChemistryNitroimidazoleOrganic ChemistryProto-Oncogene Proteins c-metProdrugCell Hypoxia0104 chemical sciences010404 medicinal & biomolecular chemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Cancer researchDrug Screening Assays AntitumorKinase bindingTyrosine kinasemedicine.drugBioorganic Chemistry
researchProduct

BCR-ABL as a target for novel therapeutic interventions.

2002

The BCR-ABL oncogene is the result of a reciprocal translocation between the long arms of chromosome 9 and 22 t(9; 22). There is good experimental evidence demonstrating that BCR-ABL is the single causative abnormality in chronic myeloid leukaemia (CML), making it a unique model for the development of molecular targets. In addition to CML, BCR-ABL transcripts can be found in a minority of acute lymphoblastic leukaemias and very rarely in acute myeloid leukaemia (AML). Elucidating the molecular mechanisms and downstream pathways of BCR-ABL has led to the design of several novel therapeutic approaches. In this review, molecular targeting of BCR-ABL will be discussed based on the inhibition of…

medicine.drug_classmedicine.medical_treatmentT-LymphocytesClinical BiochemistryFusion Proteins bcr-ablChromosomal translocationChromosome 9Antineoplastic AgentsBiologyGenes ablTyrosine-kinase inhibitorhemic and lymphatic diseasesNeoplasmsDrug DiscoverymedicineAnimalsHumansneoplasmsGenePharmacologyOncogeneImmunotherapyProtein-Tyrosine KinasesFusion proteinCell Transformation NeoplasticImmunologyMolecular MedicineSignal transductionSignal TransductionExpert opinion on therapeutic targets
researchProduct